



THE UNITED STATES OF AMERICA

TO ALL TO WHOM THESE PRESENTS SHALL COME:

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office

January 22, 2004

THIS IS TO CERTIFY THAT ANNEXED HERETO IS A TRUE COPY FROM
THE RECORDS OF THE UNITED STATES PATENT AND TRADEMARK
OFFICE OF THOSE PAPERS OF THE BELOW IDENTIFIED PATENT
APPLICATION THAT MET THE REQUIREMENTS TO BE GRANTED A
FILING DATE.

APPLICATION NUMBER: 60/477,453

FILING DATE: June 10, 2003

RELATED PCT APPLICATION NUMBER: PCT/US03/36292

REC'D 26 JAN 2004
WIPO PCT

By Authority of the
COMMISSIONER OF PATENTS AND TRADEMARKS



M. K. HAWKINS
Certifying Officer



PRIORITY DOCUMENT
SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH
RULE 17.1(a) OR (b)

17513
06/10/03
U.S. PTO
15095

06-11-03

PTO/SB/16 (05-03)

Approved for use through 4/30/2003. OMB 0651-0032

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

PROVISIONAL APPLICATION FOR PATENT COVER SHEET

This is a request for filing a PROVISIONAL APPLICATION FOR PATENT under 37 CFR 1.53(c).

Express Mail Label No. EV 342609100 US

17513
06/10/03
U.S. PTO
15095

INVENTOR(S)		
Given Name (first and middle if any)	Family Name or Surname	Residence (City and either State or Foreign Country)
Gaetano T. Robert M.	Montellione Krug	Highland Park, New Jersey Austin, Texas
Additional inventors are being named on the _____ separately numbered sheets attached hereto		
TITLE OF THE INVENTION (500 characters max)		
PROCESS FOR DESIGNING INHIBITORS OF THE LIFE CYCLE OF INFLUENZA A VIRUS TARGETED TO THE VIRAL NON-STRUCTURAL PROTEIN 1		
Direct all correspondence to: CORRESPONDENCE ADDRESS		
<input checked="" type="checkbox"/> Customer Number	<input type="text"/>	 000530 <small>Customer Number Bar Code</small>
OR		
<input type="checkbox"/> Firm or Individual Name		
Address		
City	State	Zip
Country	Telephone	Fax
ENCLOSED APPLICATION PARTS (check all that apply)		
<input checked="" type="checkbox"/> Specification Number of Pages	3	<input type="checkbox"/> CD(s), Number
<input type="checkbox"/> Drawing(s) Number of Sheets		<input type="checkbox"/> Other:
<input checked="" type="checkbox"/> Application Data Sheet. See 37 CFR 1.76		
METHOD OF PAYMENT OF FILING FEES FOR THIS PROVISIONAL APPLICATION FOR PATENT		
<input checked="" type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27.	FILING FEE AMOUNT (\$)	
<input type="checkbox"/> A check or money order is enclosed to cover the filing fees.		
<input checked="" type="checkbox"/> The Director is hereby authorized to charge filing fees or credit any overpayment to Deposit Account Number:	12-1095	80.00
<input type="checkbox"/> Payment by credit card. Form PTO-2038 is attached.		
The invention was made by an agency of the United States Government or under a contract with an agency of the United States Government.		
<input type="checkbox"/> No	<input checked="" type="checkbox"/> Yes, the name of the U.S. Government agency NIH - GM47014; AI11772 and the Government contract number are:	

[Page 1 of 1]

Date June 10, 2003

Respectfully submitted,

SIGNATURE

Gerard P. Norton

TYPED OR

PRINTED NAME

Gerard P. Norton

TELEPHONE

(908) 518-6384

REGISTRATION NO.
(if appropriate)

36,621

Docket Number:

OCIRS 3.6-081

USE ONLY FOR FILING A PROVISIONAL APPLICATION FOR PATENT

Application Data Sheet

Application Information

Application Type::	Provisional
Subject Matter::	Utility
Suggested Group Art Unit::	N/A
CD-ROM or CD-R?::	None
Sequence submission?::	None
Computer Readable Form (CRF)?::	No
Title::	PROCESS FOR DESIGNING INHIBITORS OF THE LIFE CYCLE OF INFLUENZA A VIRUS TARGETED TO THE VIRAL NON- STRUCTURAL PROTEIN 1.
Attorney Docket Number::	OCIRS 3.8-081
Request for Early Publication?::	No
Request for Non-Publication?::	No
Total Drawing Sheets::	0
Small Entity?::	Yes
Petition included?::	No
Licensed US Govt. Agency::	NIH
Contract or Grant Numbers::	GM47014; AI11772
Secrecy Order in Parent Appl.?::	No

Applicant Information

Applicant Authority Type::	Inventor
Primary Citizenship Country::	US
Status::	Full Capacity
Given Name::	Gaetano
Middle Name::	T.
Family Name::	Montelione
City of Residence::	Highland Park
State or Province of Residence::	NJ

Country of Residence:: US
Street of mailing address:: 127 N. Fifth Avenue
City of mailing address:: Highland Park
State or Province of mailing address:: NJ
Postal or Zip Code of mailing address:: 08904

Applicant Authority Type:: Inventor
Primary Citizenship Country:: US
Status:: Full Capacity
Given Name:: Robert
Middle Name:: M.
Family Name:: Krug
City of Residence:: Austin
State or Province of Residence:: TX
Country of Residence:: US
Street of mailing address:: 8200 Talbot Lane
City of mailing address:: Austin
State or Province of mailing address:: TX
Postal or Zip Code of mailing address:: 78746

Correspondence Information

Correspondence Customer Number:: 000530

Representative Information

Representative Customer Number:: 000530

Assignee Information

Assignee name:: Rutgers, The State University
Street of mailing address:: Old Queens, Somerset Street
City of mailing address:: New Brunswick
State or Province of mailing address:: NJ

Postal or Zip Code of mailing address:: 08903

**PROCESS FOR DESIGNING INHIBITORS
OF THE LIFE CYCLE OF INFLUENZA A VIRUS
TARGETED TO THE VIRAL NON-STRUCTURAL PROTEIN 1**

**The Multiple Functions Of The NS1 Protein Of Influenza A Virus (NS1A Protein) In The
Intracellular War Between The Virus And Human Cells**

The intracellular war between influenza A virus and human cells is comprised of several battles, and the viral NS1A protein plays a major role in many of these battles. The first battle: infection of human cells by influenza A virus activates the interferon (IFN)-independent transcription of antiviral genes mediated by activated interferon regulatory factor-3 (IRF-3) transcription factor. The NS1A protein counters this cellular antiviral response at the post-transcriptional level by binding cellular proteins required for the 3' end processing of cellular pre-mRNAs. Mature antiviral mRNAs are not made unless the virus encodes a NS1A protein with a mutated effector domain binding site for one of these cellular factors (CPSF). This mutation also affects a second cellular antiviral response; IFN-beta mRNA is produced earlier and in larger amounts, because post-transcriptional processing of cellular pre-mRNAs is not inhibited throughout infection. In addition, the NS1A protein is localized in the cytoplasm, indicating that CPSF binding mediates nuclear import/retention of the NS1A protein. Another sequence in the NS1A effector domain, the nuclear export signal (NES, amino acids 137-146) plays an important role, because a recombinant virus encoding a NS1A protein with a mutated NES is substantially attenuated. The N-terminal RNA-binding domain, which binds double-stranded RNA (dsRNA) with low affinity, plays a different role, as demonstrated using recombinant viruses that encode NS1A proteins whose only defect is in RNA-binding: PKR, expressed constitutively in the absence of IFN, is activated, eIF2-

alpha is phosphorylated, and viral protein synthesis is inhibited. After its activation, PKR is degraded.

The RNA Binding Domain Of The NS1 Protein Of Influenza A Virus: Identification Of One Of Its Functions During Virus Infection

The NS1 protein of influenza A virus (NS1A protein) plays a major role in the intracellular war between the virus and human cells. Functions of the effector domain of the NS1A protein, which comprises the C-terminal two-thirds of the protein, have been elucidated. In contrast, the function of the N-terminal RNA-binding domain of the NS1A protein, which binds dsRNA with low affinity, has not been established. For example, it does not sequester dsRNA to prevent the activation of either IRF-3 or NF-kappaB. Here we determine whether dsRNA binding by this domain prevents activation of PKR during infection. Activated PKR phosphorylates the translation initiation factor eIF2 α , resulting in the inhibition of protein synthesis and virus replication. Substantial amounts of PKR, which can be activated by dsRNA or by specific proteins, are expressed constitutively in the absence of interferon.

Previous results from others indicated that the amino acids of the NS1A protein that participate in the inhibition of PKR do not include those that are required for RNA binding. We generated recombinant A/Udorn/72 viruses that encode NS1A proteins whose only defect is in RNA binding. Because the R at position 38 (R38) and K41 are the only amino acids that are required solely for RNA binding, we substituted A for either one or both of these amino acids. The three mutant viruses are highly attenuated: the R38 and K41 mutant viruses form pin-point plaques, and the double mutant (R38/K41) does not form visible plaques. During high multiplicity infection of A549 cells with any of these mutant viruses, PKR is activated, eIF2 α is phosphorylated, and viral protein synthesis is inhibited. Surprisingly, after its activation, PKR is degraded. The R38/K41 double mutant is most effective in inducing PKR

activation. We conclude that one of the intracellular functions of the RNA-binding domain of the NS1A protein is to prevent the activation of PKR by binding dsRNA.

435169_1.DOC